FEMASYS INC
Close on Oct 19, 2026
- Market cap
- $5.47M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | After market close | $331.83K | $-1.33 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 8, 2026 | After market close | $424.89K | $0.00 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | After market close | $729.39K | $-0.10 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 8, 2025 | After market close | $409.27K | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $341.26K | $-0.23 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | $554.91K | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Mar 27, 2025, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| U.S. revenue | first quarter of 2025 | 50% growth | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Femasys filed with the SEC
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Femasys Regains Compliance with Nasdaq Listing Requirements
Other events · EX-99.1 to Form 8-K
CONFIDENTAIL | NASDAQ: FEMY 1 CORPORATE PRESENTATION May 2026 ©️ 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth
Executive or director change · Other events · EX-99.1 to Form 8-K
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue ® Diagnostic Device
Other events · EX-99.1 to Form 8-K
Femasys Announces Third Quarter Financial Results for 2025
Results of operations · EX-99.1 to Form 8-K
Femasys Advances Global Growth with Second Partner Order for FemBloc Ò in Europe
Other events · EX-99.1 to Form 8-K
Femasys Secures FDA Approval to Advance Final FemBloc Ò Trial Phase
Other events · EX-99.1 to Form 8-K
Femasys Secures UK Regulatory Approval of FemBloc ® Permanent Birth Control
Other events · EX-99.1 to Form 8-K
Femasys Announces Second Quarter Financial Results for 2025
Results of operations · EX-99.1 to Form 8-K
Femasys Secures First European Order for FemBloc ® , Marking Strategic Milestone in Global Expansion
Other events · EX-99.1 to Form 8-K
Femasys Announces Historic Milestone with European Approval of
Other events · EX-99.1 to Form 8-K
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
Other events · EX-99.1 to Form 8-K
Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Femasys Secures Distribution Partnerships for Commercialization of FemBloc ® in Spain
Other events · EX-99.1 to Form 8-K
Femasys Announces FemBloc ® Delivery System Approval in Europe; A Significant Step
Other events · EX-99.1 to Form 8-K
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K/A
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Investor presentation October 2024 NASDAQ: FEMY Disrupting Convention in Women’s
Regulation FD disclosure · EX-99.1 to Form 8-K
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed ® for over $1.3M in Spanish Market
Other events · EX-99.1 to Form 8-K
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec ® , an Innovative Diagnostic Solution for Fallopian
Other events · EX-99.1 to Form 8-K
Investor presentation August 2024 NASDAQ: FEMY Disrupting Convention in
Regulation FD disclosure · EX-99.1 to Form 8-K
Femasys Announces CE Mark and Canadian Approval for FemVue ® MINI, a Fallopian Tube Assessment Solution
Other events · EX-99.1 to Form 8-K
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Femasys Receives CE Mark Approval for Four of its Women’s Health Products, Clearing the Path for the Company to Begin Commercialization
Other events · EX-99.1 to Form 8-K
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Investor presentation April 2024 NASDAQ: FEMY Disrupting Convention in
Regulation FD disclosure · EX-99.1 to Form 8-K
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed ® for the Treatment of Infertility
Other events · EX-99.1 to Form 8-K
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
Other events · EX-99.1 to Form 8-K
Disrupting Convention in Women’s Health Through Continuous Innovation February 2024 Corporate
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
Other events · EX-99.1 to Form 8-K
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
Other events · EX-99.1 to Form 8-K
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
Material agreement · Listing notice · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Femasys Inc. Announces Financial Results for the Third Quarter Ended
Results of operations · EX-99.1 to Form 8-K